Lund, Sweden—October 4, 2016—Dignitana (http://www.dignitana.se/eng/) AB,
a
world leader in medical scalp-cooling technology, announced today that
the
DigniCap (https://www.dignicap.com/)® scalp cooling system, which was
cleared in
2015 by the FDA to effectively reduce the likelihood of
chemotherapy-induced
hair loss in women with breast cancer, will be available
at all five
Breastlink (http://www.breastlink.com/) centers in the U.S.  The
DigniCap®
system is the first and only scalp cooling device to complete
rigorous FDA
clinical trials in America, where seven out of ten patients with
early-stage
breast cancer kept at least 50% of their hair.

On the heels of the
FDA Clearance, medical centers across the country have begun
offering the
DigniCap® scalp cooling system as part of the comprehensive cancer
care
treatment services they provide. Through funding from a recent
Private
Placement and Rights Offering, Dignitana’s US presence is rapidly
expanding as
demand for the medical device accelerates. Breastlink, a
comprehensive breast
health center with five locations in Southern California
will be offering
DigniCap® scalp cooling systems as part of their breast cancer
treatment and
care regimens. Breastlink offers women a comprehensive breast
cancer risk
assessment program to help empower them about their health care
options.

DigniCap® scalp cooling system will be offered in all of the
Breastlink Health
Centers. Locations are as follows:

  ·
Breastlink (http://www.breastlink.com/centers/breastlink-laguna
-hills/) Laguna
Hills, California

  ·
     Breastlink (http://www.breastlink.com/centers/breastlink-temecula
-valley/) Teme
     cula
Valley, California

  ·
     Breastlink (http://www.breastlink.com/centers/breastlink-newport
-beach/) Newpor
     t
Beach, California

  ·
     Breastlink (http://www.breastlink.com/centers/breastlink-orange/) Orange,
Califo
     rnia


 ·
     Breastlink (http://www.breastlink.com/centers/breastlink-encino/) Encino,
Califo
     rnia

“We
are pleased with the consistent strong growth we are experiencing in the
U.S.
since FDA clearance nine months ago,” said Jan Richardsson, Chief
Executive
Officer of Dignitana. “The DigniCap system is being included as an
integral part
of the treatments offered by national leaders in comprehensive
breast health
services in the U.S. Up to date, forty-seven DigniCap
scalp-cooling systems have
been ordered for installation by US customers.”

The
DigniCap® scalp cooling system features a patented tight-fitting
silicone
cooling cap that is placed directly on the head, and an outer neoprene
cap that
insulates and secures the silicone cap. The cooling cap is connected
to a
cooling and control unit with touch screen prompts. A liquid coolant
circulates
throughout the silicone cap, delivering consistent and controlled
cooling to all
areas of the scalp. The cap is fitted to the head, and the
temperature of the
scalp is lowered, resulting in vasoconstriction with reduced
delivery of
chemotherapy to the scalp, as well as reduced cellular uptake of
drugs due to
decreased intra follicular metabolic rate. These factors together
reduce the
risk of chemotherapy-induced hair loss.
För ytterligare information
vänligen kontakta:

Jan Richardsson
VD, Dignitana AB (publ)

Telefon: 046-16 30
92
E-post: jan.richardsson@dignitana.se
Om Dignitana AB (publ)
Dignitanas, med
säte i Lund, affärsidé är att utveckla, tillverka och
marknadsföra den
medicintekniska produkten DigniCap®. Dignitana bedriver en
kontinuerlig
forskning och utveckling av nya användningsområden för DigniCap®.
Dignitanas
aktier handlas på NASDAQ OMX First North med Erik Penser Bank som
Certified
Adviser. För mer information gå in på: www.dignitana.se

Om
skalpkylningssystemet DigniCap®
Dignitanas huvudprodukt - skalpkylningssystemet
DigniCap® - är ett patenterat
system med syfte att eliminera eller kraftigt
reducera håravfall för patienter
som genomgår cytostatikabehandling. DigniCap®
erbjuder skalpkylning med jämn
kyla, hög effektivitet, säkerhet och acceptabel
komfort.